...merge with Zapaq to form a company focused on Alzheimer's disease and other neurology indications. Zapaq... ...Sanderling is the lead investor in both companies. Athenagen Inc. , South San Francisco, Calif. Zapaq Inc....
...Athenagen (South San Francisco, Calif.) plans to merge with Zapaq (Waltham, Mass.) to form a company... ...Waltham, Mass.) to form a company focused on Alzheimer's disease (AD) and other neurology indications. Zapaq...
...program. On Monday this week, the company planned to announce another deal: a merger with Zapaq Inc.... ...be a difficult target because it is associated with more toxicity than beta, he said. Zapaq... ...Oct. 9, 2000). The company mimicked the conformation of the protein to design selective inhibitors. "Zapaq...
...merge with Zapaq to form a company focused on Alzheimer's disease and other neurology indications. Zapaq... ...Sanderling is the lead investor in both companies. Athenagen Inc. , South San Francisco, Calif. Zapaq Inc....
...Athenagen (South San Francisco, Calif.) plans to merge with Zapaq (Waltham, Mass.) to form a company... ...Waltham, Mass.) to form a company focused on Alzheimer's disease (AD) and other neurology indications. Zapaq...
...program. On Monday this week, the company planned to announce another deal: a merger with Zapaq Inc.... ...be a difficult target because it is associated with more toxicity than beta, he said. Zapaq... ...Oct. 9, 2000). The company mimicked the conformation of the protein to design selective inhibitors. "Zapaq...
